Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024

PRECIGEN, INC.

2024-Q1 EPS reported -$0.10

Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.
Cash, equivalents, and short-term investments $44.8M; evaluating financing options to strengthen balance sheet.
PRGN-2012 pivotal Phase 2 data as late-breaking oral at ASCO June 3; rolling BLA submission expected H2 2024.
Commercial readiness activities underway for potential PRGN-2012 launch in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for first quarter 2024.

Period: first quarter 2024
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 14, 2024, reporting its financial results for the quarter ended March 31, 2024.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-24-006675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.